Thermo Fisher Scientific Inc (TMO)
580.05
-4.10
(-0.70%)
USD |
NYSE |
Mar 18, 16:00
579.95
-0.10
(-0.02%)
Pre-Market: 07:23
Thermo Fisher Scientific Enterprise Value: 248.13B for March 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 18, 2024 | 248.13B |
March 15, 2024 | 249.69B |
March 14, 2024 | 249.98B |
March 13, 2024 | 253.19B |
March 12, 2024 | 254.69B |
March 11, 2024 | 255.52B |
March 08, 2024 | 254.82B |
March 07, 2024 | 254.84B |
March 06, 2024 | 252.49B |
March 05, 2024 | 249.87B |
March 04, 2024 | 248.73B |
March 01, 2024 | 246.71B |
February 29, 2024 | 244.36B |
February 28, 2024 | 245.07B |
February 27, 2024 | 242.83B |
February 26, 2024 | 241.81B |
February 23, 2024 | 242.28B |
February 22, 2024 | 240.67B |
February 21, 2024 | 237.76B |
February 20, 2024 | 235.96B |
February 16, 2024 | 235.85B |
February 15, 2024 | 236.12B |
February 14, 2024 | 236.01B |
February 13, 2024 | 232.32B |
February 12, 2024 | 235.47B |
Date | Value |
---|---|
February 09, 2024 | 236.95B |
February 08, 2024 | 237.01B |
February 07, 2024 | 237.55B |
February 06, 2024 | 240.59B |
February 05, 2024 | 237.29B |
February 02, 2024 | 240.31B |
February 01, 2024 | 240.47B |
January 31, 2024 | 235.34B |
January 30, 2024 | 246.22B |
January 29, 2024 | 242.61B |
January 26, 2024 | 238.57B |
January 25, 2024 | 235.04B |
January 24, 2024 | 235.73B |
January 23, 2024 | 239.89B |
January 22, 2024 | 240.91B |
January 19, 2024 | 240.28B |
January 18, 2024 | 237.45B |
January 17, 2024 | 235.45B |
January 16, 2024 | 236.51B |
January 12, 2024 | 237.41B |
January 11, 2024 | 238.06B |
January 10, 2024 | 237.26B |
January 09, 2024 | 236.45B |
January 08, 2024 | 236.27B |
January 05, 2024 | 232.35B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
117.17B
Minimum
Mar 23 2020
293.76B
Maximum
Dec 31 2021
204.45B
Average
219.31B
Median
Enterprise Value Benchmarks
Fonar Corp | 78.80M |
XWELL Inc | -10.27M |
ProPhase Labs Inc | 96.78M |
Applied DNA Sciences Inc | 4.008M |
OncoCyte Corp | 11.14M |
Enterprise Value Related Metrics
Net Income (Quarterly) | 1.63B |
Revenue (Quarterly) | 10.89B |
Total Expenses (Quarterly) | 8.952B |
EPS Diluted (Quarterly) | 4.20 |
Gross Profit Margin (Quarterly) | 40.35% |
Profit Margin (Quarterly) | 14.97% |
Earnings Yield | 2.66% |
Operating Earnings Yield | 3.25% |
Normalized Earnings Yield | 2.859 |